<DOC>
	<DOC>NCT02191293</DOC>
	<brief_summary>Collecting data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) after switching from protease inhibitor or NNRTI to Nevirapine (Viramune®) and collecting of routinely observed laboratory data on lipids, and liver enzymes.</brief_summary>
	<brief_title>Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Adult male and female outpatients with HIV type 1 infection who have achieved a viral load below detection limit (50 copies/ml) for more than 6 months under a previous combination therapy with proteaseinhibitors (PI) or nonnucleoside reverse transcriptase inhibitors (NNRTI) Women can only be included, if a test has excluded pregnancy Only women can be included, who use a reliable means of contraception during the observational study Known sensitivity to Viramune or one of its excipients Clinically relevant changes in lab findings (e.g. increase in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) by more than fivefold of upper limit normal) Patient is not able to abstain from treatment with ketoconazole, oral contraceptives, and other medication CYP3A metabolism For females: Pregnancy Breastfeeding Insufficient or unreliable contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>